Circular Genomics is proud to announce the successful $8.3 Million Series A funding round, a pivotal step in advancing precision medicine for mental health.
Our portfolio company Circular Genomics raised a $ 8.3M A-round. The round is led by Mountain Group Partners. This round also welcomes new investor UNM Rainforest Innovations and existing investors including Cottonwood Technology Fund, Tramway Venture Partners, and other undisclosed individuals.
Circular Genomics has secured new funding to build and expand its operations for the launch of the world’s first circular RNA-based clinical assay. This innovative test aims to enhance the standard of care in depression treatment by predicting a patient’s likelihood to respond to antidepressant medications. The company plans to launch its first test in 2024, focusing on predicting the response to SSRI antidepressants. The goal is to address high therapy failure rates and improve clinical outcomes in depression treatment. The funding will support the development of Circular Genomics’ circular RNA biomarker platform, paving the way for personalized care in mental health and expanding into other neurological diseases. The company aims to lead the way in precision medicine for mental health, tailoring treatments to individual patients and improving overall outcomes in complex conditions.
Circular Genomics is a spin-off of The University of New Mexico and developed diagnostics for psychiatric and neurological disorders based on the analysis of circular RNAs. The Albuquerque-based firm raised $4.5 million in seed funding in late 2021.
Circular Genomics Raises $8.3 Million for Debut of Circular RNA Assay in Precision Psychiatry
